Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies
Tian‐Tian Ji,Shuai‐Shuai Niu,Ming‐Hui Fang,Ling‐Xue Xu,Xin Wang,Jun Zou,Fei Xu,Meng Zhang,Rui Niu,Jun Wu,Lei Wang,Zhi‐Kun Li,Yong‐Guang Yang,Jie Hao,Wei Li,Zheng Hu,Qi Zhou
DOI: https://doi.org/10.1111/cpr.13471
IF: 8.755
2023-05-19
Cell Proliferation
Abstract:Here, we first selected an human embryonic stem cell (hESC) line with homozygous human leucocyte antigen (HLA)‐A*11:01 allele, the most popular HLA‐I allele of the Chinese population, then generated a hypoimmunogenic hESC line by disrupting HLA‐B, HLA‐C, and CIITA genes while retaining HLA‐A*11:01 (named as HLA‐A11R hESCs), covering ~21% of the Chinese population. The immunocompatibility of the HLA‐A11R hESCs was verified by in vitro co‐culture assays and confirmed in humanized mice with an established human immune system. Moreover, to address safety issues, we precisely knocked a clinical trial‐grade drug‐induced caspase‐9 suicide cassette into HLA‐A11R hESCs, generating iC9‐HLA‐A11R hESCs, which were efficiently induced to apoptosis by AP1903. In summary, we customized an immunocompatible hESC cell line based on the HLA typing characteristics of the Chinese population with safety insurance, which provided the basis for the establishment of an HLA‐AR bank of hESCs covering broader populations in the world, speeding up the clinical application of a range of hESC‐based therapies. Robust allogeneic immune reactions after transplantation impede the translational pace of human embryonic stem cells (hESCs)‐based therapies. Selective genetic editing of human leucocyte antigen (HLA) molecules has been proposed to generate hESCs with immunocompatibility, which, however, has not been specifically designed for the Chinese population yet. Herein, we explored the possibility of customizing immunocompatible hESCs based on Chinese HLA typing characteristics. We generated an immunocompatible hESC line by disrupting HLA‐B, HLA‐C, and CIITA genes while retaining HLA‐A*11:01 (HLA‐A*11:01‐retained, HLA‐A11R), which covers ~21% of the Chinese population. The immunocompatibility of HLA‐A11R hESCs was verified by in vitro co‐culture and confirmed in humanized mice with established human immunity. Moreover, we precisely knocked an inducible caspase‐9 suicide cassette into HLA‐A11R hESCs (iC9‐HLA‐A11R) to promote safety. Compared with wide‐type hESCs, HLA‐A11R hESC‐derived endothelial cells elicited much weaker immune responses to human HLA‐A11+ T cells, while maintaining HLA‐I molecule‐mediated inhibitory signals to natural killer (NK) cells. Additionally, iC9‐HLA‐A11R hESCs could be induced to undergo apoptosis efficiently by AP1903. Both cell lines displayed genomic integrity and low risks of off‐target effects. In conclusion, we customized a pilot immunocompatible hESC cell line based on Chinese HLA typing characteristics with safety insurance. This approach provides a basis for establishment of a universal HLA‐AR bank of hESCs covering broad populations worldwide and may speed up the clinical application of hESC‐based therapies.
cell biology